These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 941742)

  • 21. Letter: Catecholamines in the median eminence: new evidence for a major noradrenergic input.
    Cuello AC; Horn AS; Mackay AV; Iversen LL
    Nature; 1973 Jun; 243(5408):465-7. PubMed ID: 4743641
    [No Abstract]   [Full Text] [Related]  

  • 22. L-dopa in Parkinsonism. A possible mechanism of action.
    Ng LK; Chase TN; Colburn RW; Kopin IJ
    Neurology; 1972 Jul; 22(7):688-96. PubMed ID: 4673250
    [No Abstract]   [Full Text] [Related]  

  • 23. Catecholamines and convulsions.
    Mason ST; Corcoran ME
    Brain Res; 1979 Jul; 170(3):497-507. PubMed ID: 466425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of 2-(2-benzofuranyl)-2-imidazoline (2-BFI) on dopamine synthesis in rat striatum in vivo.
    Sastre-Coll A; Esteban S; García-Sevilla JA
    Ann N Y Acad Sci; 1999 Jun; 881():364. PubMed ID: 10415937
    [No Abstract]   [Full Text] [Related]  

  • 25. An evaluation of various antiparkinsonian agents as releasing agents and uptake inhibitors for 3H-dopamine in slices of rat neostriatum.
    Orlansky H; Heikkila RE
    Eur J Pharmacol; 1974 Dec; 29(2):284-91. PubMed ID: 4442446
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of amantadine as a releasing agent or uptake blocker for H 3 -dopamine in rat brain slices.
    Heikkila RE; Cohen G
    Eur J Pharmacol; 1972 Nov; 20(2):156-60. PubMed ID: 4651205
    [No Abstract]   [Full Text] [Related]  

  • 27. Correlation between central catecholamine level and post-decapitation convulsion in rats treated with 6-hydroxydopamine.
    Suenaga N; Yamada K; Fukuda T
    Brain Res; 1977 Feb; 122(1):165-9. PubMed ID: 837220
    [No Abstract]   [Full Text] [Related]  

  • 28. Is drug inhibition of dopamine uptake a misinterpretation of in vitro experiments?
    Bauman PA; Maitre L
    Nature; 1976 Dec 23-30; 264(5588):789-90. PubMed ID: 1012321
    [No Abstract]   [Full Text] [Related]  

  • 29. Presence of dopaminergic terminals and absence of dopaminergic cell bodies in the cerebral cortex of the cat.
    Thierry AM; Hirsch JC; Tassin JP; Blanc G; Glowinski J
    Brain Res; 1974 Oct; 79(1):77-88. PubMed ID: 4425954
    [No Abstract]   [Full Text] [Related]  

  • 30. Enhancement by 6-hydroxydopamine of the effects of DOPA upon the motor activity of rats.
    Schoenfeld RI; Uretsky NJ
    J Pharmacol Exp Ther; 1973 Sep; 186(3):616-24. PubMed ID: 4728340
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential effects of xylamine on extracellular concentrations of norepinephrine and dopamine in rat central nervous system: an in vivo electrochemical study.
    Howard-Butcher S; Blaha CD; Lane RF
    J Pharmacol Exp Ther; 1985 Apr; 233(1):58-63. PubMed ID: 3981462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of desipramine on rat cortex slices incubated with 3H-dopamine.
    Gerlach J; Nielsen M; Randrup A
    Psychopharmacologia; 1974; 37(4):341-9. PubMed ID: 4851622
    [No Abstract]   [Full Text] [Related]  

  • 33. Selective activation of mesocortical DA system by stress.
    Thierry AM; Tassin JP; Blanc G; Glowinski J
    Nature; 1976 Sep; 263(5574):242-4. PubMed ID: 958479
    [No Abstract]   [Full Text] [Related]  

  • 34. Dopamine and norepinephrine enhancement in discrete rat brain regions following neonatal 6-hydroxydopamine treatment.
    Oke A; Keller R; Adams RN
    Brain Res; 1978 Jun; 148(1):245-50. PubMed ID: 656929
    [No Abstract]   [Full Text] [Related]  

  • 35. Ingestive behavior following damage to central dopamine neurons: implications for homeostasis and recovery of function.
    Zigmond MJ; Stricker EM
    Adv Biochem Psychopharmacol; 1974; 12(0):385-402. PubMed ID: 4609140
    [No Abstract]   [Full Text] [Related]  

  • 36. Specific lysis by 6-hydroxydopamine of catecholaminergic synaptosomes prepared from rat cerebrum.
    Suzuki T; Okumura-Noji K; Tanaka R
    Brain Res; 1984 Nov; 321(2):374-6. PubMed ID: 6437604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mesolimbic dopaminergic neurones in the rotational model of nigrostriatal function.
    Kelly PH; Moore KE
    Nature; 1976 Oct; 263(5579):695-6. PubMed ID: 980114
    [No Abstract]   [Full Text] [Related]  

  • 38. Proceedings: Increase in the cyclic AMP content of rat striatum produced by a cyclic analogue of dopamine.
    Munday KA; Poat JA; Woodruff GN
    J Physiol; 1974 Sep; 241(2):119P-120P. PubMed ID: 4374521
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term effects of unilateral 6-hydroxydopamine destruction of the dopaminergic nigrostriatal pathway on the urinary excretion of catecholamines (dopamine, norepinephrine, epinephrine) and their metabolites in the rat.
    Peyrin L; Cottet-Emard JM; Javoy F; Agid Y; Herbet A; Glowinski J
    Brain Res; 1978 Mar; 143(3):567-72. PubMed ID: 274167
    [No Abstract]   [Full Text] [Related]  

  • 40. Dopamine and norepinephrine innervated cells in the rat prefrontal cortex: pharmacological differentiation using microiontophoretic techniques.
    Bunney BS; Aghajanian GK
    Life Sci; 1976 Dec; 19(11):1783-9. PubMed ID: 1004134
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.